Moderna Q3 Revenue Beats On Updated COVID-19 Vaccine, Slashes Expenses For 2024

On Thursday, Moderna Inc (NASDAQ:MRNA) stock is trading higher after the company reported better-than-expected third-quarter sales.

Moderna reported third-quarter revenue of $1.83 billion, compared with $1.83 billion a year earlier, beating the consensus of $1.25 billion.

The company attributed the growth to higher sales in the U.S. market following the earlier launch of the updated COVID-19 vaccine.

With FDA approval granted three weeks earlier than in the previous year, the company was able to meet demand more effectively.

Also Read: Struggling COVID-19 Vaccines From AstraZeneca, BioNTech/Pfizer, Moderna Cut Incidence Of Arterial Thromboses That Cause Heart Attacks, Strokes, British Study Shows

Moderna reported $1.8 billion in Spikevax sales in the third quarter of 2024, which ...